Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
about
Which anticholinergic drug for overactive bladder symptoms in adultsAnticholinergic drugs versus placebo for overactive bladder syndrome in adultsWhich anticholinergic drug for overactive bladder symptoms in adultsTotal urgency and frequency score as a measure of urgency and frequency in overactive bladder and storage lower urinary tract symptomsPharmacoeconomic evaluation of antimuscarinic agents for the treatment of overactive bladderAdverse event assessment of antimuscarinics for treating overactive bladder: a network meta-analytic approachThe importance of screening, assessing, and managing urinary incontinence in primary care.Solifenacin significantly improves all symptoms of overactive bladder syndrome.The analysis of incontinence episodes and other count data in patients with overactive bladder by Poisson and negative binomial regression.A meta-analysis of the placebo response in antimuscarinic drug trials for overactive bladder.Oxybutynin and tolterodine in a trial for treatment of overactive bladder in Iranian womenComparison of selective M3 and nonselective muscarinic receptor antagonists on gastrointestinal transit and bowel habits in humansCost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry.The placebo effect in overactive bladder syndrome.Role of inflammation in bladder function and interstitial cystitis.Office management of urinary incontinence among older patientsThe overlap of interstitial cystitis/painful bladder syndrome and overactive bladderTolterodine extended release in the treatment of male OAB/storage LUTS: a systematic review.Evidence for the efficacy and safety of tolterodine in the treatment of overactive bladder.Muscarinic receptors in the bladder: from basic research to therapeutics.Tolterodine extended-release for overactive bladder.Overactive bladder: a challenge for primary care.Emerging drugs for treatment of urinary incontinence.Current pharmacotherapeutic strategies for overactive bladder.Urodynamic detrusor overactivity in patients with overactive bladder symptoms.The role of combination medical therapy in benign prostatic hyperplasia.Cytochrome P450 Enzyme Metabolites in Lead Discovery and Development.Muscarinic receptors: their distribution and function in body systems, and the implications for treating overactive bladderOxybutynin for treatment of urge urinary incontinence and overactive bladder: an updated review.Tolterodine for the treatment of overactive bladder: a review.Role of muscarinic receptor antagonists in urgency and nocturia.A review and additional post-hoc analyses of the incidence and impact of constipation observed in darifenacin clinical trialsThe emergence of new drugs for overactive bladder.The overactive bladder: review of current pharmacotherapy in adults. Part 1: pathophysiology and anticholinergic therapy.Developments in pharmacological therapy for the overactive bladder.Current and emerging investigational medical therapies for the treatment of overactive bladder.Effect of anticholinergic use for the treatment of overactive bladder on cognitive function in postmenopausal womenRedefining response in overactive bladder syndrome.Anticholinergic use in children: Persistence and patterns of therapy.Efficacy and tolerability of combined medication of two different antimuscarinics for treatment of adults with idiopathic overactive bladder in whom a single agent antimuscarinic therapy failed
P2860
Q24203880-581D7176-36C5-460B-B3E2-1B2015AC08C4Q24243870-0E2E1354-70D4-4BF2-BC83-87C407C9B275Q24246651-9ED8B61A-05E1-48EC-83B3-E291158D62F3Q27001248-D7628A05-879D-47F7-BE64-469A07809005Q28275473-8E822720-F974-4BCC-AA61-5383371B9D21Q28742444-907248B5-BD50-4D35-934D-4814F9FDD0C8Q30310770-F4F969E2-B572-4419-8117-09762FE25383Q30445725-28FB21B2-E418-4D2E-9C45-CBE90BEC9F49Q30880978-339A1F90-D63B-4054-92E1-917C09CAE0E9Q33485538-6F15393D-CB27-4602-92AA-AE7860F94B5DQ33783024-C48AE38D-706D-4D45-BEC4-1D36C6EB2E34Q33994796-FC99AD9F-3ADC-477A-8E23-5FF5AEF4C021Q34077022-88B0F2E1-EF1C-4C5B-B7F4-8CC8D86B10D3Q34197411-7B67F47F-AAC0-43D8-88F8-A861A2B74452Q34203459-18C3DB13-AFAC-490F-A8F7-27AF80ECD99EQ34305631-BF790B71-DB0A-4173-8050-93FCEDB5B313Q34492081-4BECCE01-D2F5-426C-869D-F1BB304F56B5Q34502903-567FBD16-72D1-48D1-AE47-4A0378C29A45Q34515443-137C1D64-4B11-48E0-87F2-5FEAF3B3761EQ34564708-45556001-425A-47D9-9964-C130AB475035Q34610640-BA3BD36B-B837-4436-88DB-E259CEEB3E8FQ34616647-820B38A8-E4A5-468D-91DF-4AF0C694C026Q34618648-3DC4311F-965C-4917-B836-A8A657D887E3Q34706864-A1E8DED6-0B46-4043-AC0C-CFCC8576797AQ34758302-A6A9FE97-312D-4F62-8ED2-37F02CFE9819Q34877827-FB4C4059-2481-4904-8B07-F0BA6A89AC9CQ35194778-1CF3C2A2-1CCE-4644-9399-FBE4899BF1E7Q35546189-35321062-CD23-45F7-B9E9-F5D269CACE37Q35925548-FEEDA733-BD29-40E2-BA11-394E42710D72Q36150735-07469238-4E3B-44CE-8467-12FAA93F8F12Q36219834-F1137123-9B2A-45D1-8C26-DD8F4E749966Q36307893-DDDDB7EF-F732-4E0A-AE23-F1A13AEC42F8Q36407417-6E3725D9-A722-4B60-9662-5CB9EF7D8A08Q36428471-118732C4-D12D-474E-AA61-C25046EC65BCQ36566857-26C45A50-5271-4743-B5BE-54C96C209DF2Q36568728-A028B1F0-FC02-46B7-92A1-3904ED230783Q36611322-047FC3EC-590C-46AE-B872-1D185BEA060AQ36709649-743EC82F-10D7-4068-82B8-4DB6B4C685F0Q36823081-37ACEE66-B6C7-49C3-9801-5B5FCF8FD03BQ36833843-E259DEA9-3063-48EF-AF6F-4CAF60ACAC57
P2860
Tolterodine once-daily: superior efficacy and tolerability in the treatment of the overactive bladder.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh-hant
name
Tolterodine once-daily: superi ...... ent of the overactive bladder.
@en
Tolterodine once-daily: superi ...... ent of the overactive bladder.
@nl
type
label
Tolterodine once-daily: superi ...... ent of the overactive bladder.
@en
Tolterodine once-daily: superi ...... ent of the overactive bladder.
@nl
prefLabel
Tolterodine once-daily: superi ...... ent of the overactive bladder.
@en
Tolterodine once-daily: superi ...... ent of the overactive bladder.
@nl
P2093
P1433
P1476
Tolterodine once-daily: superi ...... ment of the overactive bladder
@en
P2093
P Van Kerrebroeck
Tolterodine Study Group
P304
P356
10.1016/S0090-4295(00)01113-4
P407
P577
2001-03-01T00:00:00Z